|
CELECOXIB | ||
PRODUCT IDENTIFICATION | ||
CAS NO. | 169590-42-5, 184007-95-2, 194044-54-7 |
|
EINECS NO. | ||
FORMULA | C17H14F3N3O2S | |
MOL WT. | 381.38 | |
H.S. CODE |
2935.00.6000 | |
TOXICITY |
||
SYNONYMS | Celebra; Celebrex; Niflam; | |
4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide; 4-(1,1,1-trifluoromethyl - 5-(4-methylphenyl) pyrazol-1-yl)- benzenesulfonamide; | ||
SMILES |
n1(c(c2ccc(cc2)C)cc(n1)C(F)(F)F)c1ccc(cc1)S(=O)(=O)N | |
CLASSIFICATION |
Analgesic Non-Narcotic, Annti-Inflammatory Agent Non-Steroidal; Antirheumatic Agent, COX-2 inhibitor, Cyclooxygenase Inhibitor | |
EXTRA NOTES |
Celecoxib is a non-steroidal, anti-inflammatory drug (NSAID) and a cyclooxygenase-2 (COX-2) selective inhibitor. Celecoxib is at least 10-20 times more selective for COX-2 over COX-1. |
|
PHYSICAL AND CHEMICAL PROPERTIES |
||
PHYSICAL STATE | yellow crystalline powder | |
MELTING POINT | 157 - 158 C | |
BOILING POINT | ||
SPECIFIC GRAVITY | ||
SOLUBILITY IN WATER | Insoluble | |
pH | ||
VAPOR DENSITY |
|
|
log P | 3.47 (octanol-water) | |
AUTOIGNITION |
|
|
NFPA RATINGS |
||
REFRACTIVE INDEX |
|
|
FLASH POINT | ||
STABILITY |
Stable under ordinary conditions |
|
EXTERNAL LINKS & GENERAL DESCRIPTION |
||
Drug Information Portal (U.S. National Library of Medicine) - Celecoxib http://www.latamjpharm.org/ Local: Nonsteroidal Antiinflammatory Drugs (NSAIDs); chemically heterogeneous large groups of drugs which suppress inflammation in a manner similar to steroids, but less side effects of sedation, respiratory depression, or addiction than steroids. They are widely used for the treatment of inflammatory disorders and painful conditions such as rheumatoid arthritis, gout, bursitis, painful menstruation, and headache. They are effective in the relief of pain and fever. NSAIDs inhibit the cyclooxygenase (COX) activity resulting in decreased synthesis of prostaglandin, leukotriene and thromboxane precursors such as the ubiquitous enzyme which catalyzes the initial step in the synthesis of prostanoids. Prostanoid is any of a group of C-20 fatty acids complex with an internal five or six carbon rings such as prostaglandins, prostanoic acid, prostacyclins, and thromboxane; derived from arachidonic acid (C-20 polyunsaturated fatty acid with four cis double bonds). The action or the synthesis of prostanoids are involved in the modulation of a variety of pathophysiologic processes including inflammation, hemostasis, thrombosis, cytoprotection, ulceration, hemodynamics and other the progression of kidney diseases. Thus, NSAIDs as non-selective inhibitors of the cyclooxygenases (both the cyclooxygenase-1 and cyclooxygenase-2 isoenzymes) may have beneficial as well as untoward effects on a variety of human diseases. Low stomach prostanoid levels caused by COX-1 inhibitors can result in ulceration and internal bleeding and perforation. The selective COX-2 inhibitors such as oxicam, meloxicam, and coxibs (celecoxib, rofecoxib, valdecoxib, parecoxib and etoricoxib) do not interfere with COX-1. The most prominent NSAID is aspirin. Nonaspirin NSAIDs can be classified based on chemical structures. Nonsteroidal Anti-Inflammatory Drugs (NSAID) by chemical structure
|
||
SALES SPECIFICATION | ||
APPEARANCE |
white powder | |
IDENTIFICATION |
Complies Test A,B |
|
ASSAY |
98.0 - 102.0% (HPLC) |
|
IMPURITY |
0.5% max |
|
SULFATED ASH |
0.005% max |
|
HEAVY METALS |
10ppm max | |
WATER |
0.5% max | |
TRANSPORTATION | ||
PACKING |
| |
HAZARD CLASS | ||
UN NO. | ||
OTHER INFORMATION | ||
Hazard Symbols: T+, Risk Phrases: 45-28-42/43, Safety Phrases: 53-36/37/39-45 |
|
|